KYLYS

KYLYS, a Life Science spin-off from the University of Geneva, was founded in March 2017. The company specializes in developing advanced hyaluronic acid (HA) based products designed to enhance safety and precision in medical and aesthetic treatments. KYLYS targets healthcare professionals and aesthetic practitioners, offering solutions that minimize post-injection side effects and maximize patient comfort. The core product, HA L PNIPAM, is a biocompatible and biodegradable gel that transitions from a fluid state at room temperature to a microgel structure at body temperature. This unique property allows for easy injection and acts as a barrier against degradation, ensuring a longer-lasting effect compared to existing water-soluble polymers. The company operates in the biotechnology and medical device market, generating revenue through the sale of its patented HA-based products. KYLYS's business model focuses on continuous innovation and collaboration with medical professionals to deliver highly effective and safe treatments. The company is driven by a passion for science and biotechnology, with a commitment to improving patient outcomes through advanced technology.

Keywords: hyaluronic acid, biocompatible gel, medical treatments, aesthetic solutions, biotechnology, University of Geneva, HA L PNIPAM, patient comfort, injectable gel, healthcare professionals.